4-Ethoxy-4-methyl-piperidine | 54009-05-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-Ethoxy-4-methyl-piperidine
• 英文别名: 4-Ethoxy-4-methylpiperidine
• CAS: 54009-05-1
• 化学式: C₈H₁₇NO
• mdl: MFCD19221981
• 分子量: 143.229
• InChiKey: MMYISEKIIWSERK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• DIAZACARBAZOLES AND METHODS OF USE
  申请人：Chen Huifen

  公开号：US20110118230A1

  公开（公告）日：2011-05-19

  The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

  本发明涉及式（I），（I-a）和（I-b）的1,7-二氮杂咔唑化合物，其作为激酶抑制剂有用，更具体地作为检查点激酶1（chk1）抑制剂有用，因此可用作癌症治疗剂。本发明还涉及包含这些化合物的组合物，更具体地是药物组合物，并使用它们治疗各种形式的癌症和增生性疾病的方法，以及使用这些化合物进行哺乳动物细胞的体外、原位和体内诊断或治疗的方法，或相关的病理条件。
• COMPOUND CONTAINING BASIC GROUP AND USE THEREOF
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1942108A1

  公开（公告）日：2008-07-09

  The present invention relates to a compound represented by formula (I): wherein all symbols are as defined here, a salt thereof, a solvate thereof, or a prodrug thereof. The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, rejection of transplanted organ, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.

  本发明涉及一种由式 (I) 代表的化合物： 其中所有符号均如本文所定义，是其盐、其溶液或其原药。 本发明的化合物对 CXCR4 具有拮抗活性，因此可用作 CXCR4 介导的疾病的预防和/或治疗剂，例如炎症性和免疫性疾病（如类风湿性关节炎、关节炎、视网膜病变、肺纤维化、移植器官的排斥反应等）。）、过敏性疾病、感染（如人类免疫缺陷病毒感染、获得性免疫缺陷综合征等）、精神神经疾病、脑部疾病、心血管疾病、代谢性疾病和癌症疾病（如癌症、癌症转移等），或再生治疗剂。
• [EN] 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES<br/>[FR] DÉRIVÉS DE 3-(5-HYDROXY-1-OXOISOINDOLINE-2-YL)PIPÉRIDINE-2,6-DIONE ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES DÉPENDANTES DU DOIGT DE ZINC 2 DE LA FAMILLE IKAROS (IKZF2)
  申请人：NOVARTIS AG

  公开号：WO2020012334A1

  公开（公告）日：2020-01-16

  The present disclosure provides a compound of Formula (I'): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Rx, X1, X2, and R1 are as defined herein, and its use in the treatment of IKAROS Family Zinc Finger 2 (IKZF2)-dependent diseases.